AM
BMRN icon

AGF Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

AGF Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-38,081
Closed -$2.69M – 640
2025
Q1 		$2.69M Sell
38,081
-1,851
-5% -$125K 0.01% 387
2024
Q4 		$2.62M Buy
39,932
+5,476
+16% +$367K 0.01% 365
2024
Q3 		$2.42M Buy
34,456
+3,326
+11% +$278K 0.01% 479
2024
Q2 		$2.56M Buy
+31,130
New +$2.59M 0.01% 342

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AGF Management's BMRN Position: Q2 2025 in Review

AGF Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 38,081 shares — an estimated $2.69M sold.

AGF Management first reported a position in BMRN in Q2 2024 and held it in 4 quarters. The position peaked at $2.69M in Q1 2025. 581 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

  • AGF Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • AGF Management sold 38,081 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $2.69M.
  • AGF Management first reported a position in BioMarin Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • AGF Management's BioMarin Pharmaceuticals position peaked at $2.69M in Q1 2025.
  • 581 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on AGF Management's 13F filing for Q2 2025, filed 6 Aug 2025.